Eli Lilly has doubled down on its partnership with Chia’s Innovent with a licensing deal for ex-China rights to Tyvyt, their PD-1 inhibitor, which some analysts think may be launched at a ...

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab ... debated” in the wake of Eli Lilly halting its own PD-1 program in RA ...

Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ farnesoid X receptor (FXR) agonist programme ... a 22.8% mean reduction ...

One of the highlights of Eli Lilly's third-quarter results ... raised the risk that it would cannibalise sales of Lilly's own GLP-1 agonist Trulicity (dulaglutide), which is competing head-to ...

This surge was largely driven by its blockbuster GLP-1 receptor agonists, Mounjaro and Zepbound, which dominate the obesity and diabetes markets. Eli Lilly’s net income doubled compared to Q4 ...

Eli Lilly) up to 24 months before pregnancy had a 45% lower risk for cesarean delivery compared with those who received a prescription for a GLP-1 receptor agonist (OR = 0.55; 95% CI, 0.37-0.83).